Peptide therapy for retinitis pigmentosa
Part of Eyes & vision, Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This trial tests a new peptide therapy for people with retinitis pigmentosa (RP), a genetic eye disease that causes vision loss. The goal is to see if the treatment is safe and can help slow or improve vision loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 65 years old
- Have a confirmed diagnosis of retinitis pigmentosa (RP)
- Have at least some vision (1/60 or better) in at least one eye
- Your eye condition and overall health have been stable for the past 6 months
- Not have other serious eye diseases like advanced glaucoma or diabetic retinopathy
- Not be pregnant or breastfeeding, and not have had eye surgery in the last 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new gene therapy that may help people with advanced retinitis pigmentosa see better. It uses a modified virus to deliver a light-sensitive protein to the retina, and the trial compares the real treatment to a sham (fake) procedure to check safety and effectiveness.
This trial tests an investigational gene therapy injection (UGX202) for people with advanced retinitis pigmentosa. The goal is to see if the injection is safe and can help preserve or improve vision in people who still have some memory of seeing.
This study tests a new gene therapy called UGX202 for people with advanced retinitis pigmentosa, an eye disease that causes vision loss. The goal is to see if it is safe and if it can help improve vision.
This trial tests a gentle laser treatment (SML) for people with retinitis pigmentosa (RP), an inherited eye disease that slowly causes vision loss. The goal is to see if the laser can help slow or improve vision problems like night blindness and tunnel vision.
This trial tests a new form of the drug pitavastatin, which is usually used for cholesterol, but here it's given as tiny particles injected into the eye. The goal is to see if it's safe and might help people with retinitis pigmentosa, a condition that causes vision loss.
This early-stage study tests a new cell-based treatment (C.001) for inherited retinal diseases that affect the back of the eye. The treatment may help slow vision loss or improve sight in people with geographic atrophy or Stargardt disease.
Hear when a new Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.